FY2029 EPS Estimates for Altimmune Reduced by HC Wainwright

Altimmune, Inc. (NASDAQ:ALT - Free Report) - HC Wainwright cut their FY2029 EPS estimates for Altimmune in a research note issued to investors on Monday, March 3rd. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of $1.26 for the year, down from their prior forecast of $1.30. HC Wainwright currently has a "Buy" rating and a $12.00 price objective on the stock. The consensus estimate for Altimmune's current full-year earnings is ($1.35) per share.

Several other research firms have also commented on ALT. UBS Group initiated coverage on shares of Altimmune in a research note on Tuesday, November 12th. They issued a "buy" rating and a $26.00 price objective for the company. William Blair initiated coverage on shares of Altimmune in a research note on Friday, February 28th. They issued a "market perform" rating for the company. Finally, Stifel Nicolaus assumed coverage on shares of Altimmune in a research note on Wednesday, January 8th. They issued a "buy" rating and a $18.00 price objective for the company. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $20.83.

Altimmune Price Performance

Shares of NASDAQ ALT traded down $0.02 during midday trading on Wednesday, hitting $5.57. The company's stock had a trading volume of 2,392,245 shares, compared to its average volume of 2,314,174. The business's fifty day simple moving average is $6.65 and its two-hundred day simple moving average is $7.16. Altimmune has a 1 year low of $5.28 and a 1 year high of $11.50. The firm has a market capitalization of $428.97 million, a price-to-earnings ratio of -3.59 and a beta of 0.87.

Remove Ads

Altimmune (NASDAQ:ALT - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.33) earnings per share for the quarter, beating analysts' consensus estimates of ($0.34) by $0.01. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. The business had revenue of $0.01 million during the quarter, compared to analysts' expectations of $0.00 million.

Institutional Trading of Altimmune

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ALT. Larson Financial Group LLC acquired a new stake in Altimmune during the third quarter worth approximately $31,000. SBI Securities Co. Ltd. acquired a new position in shares of Altimmune in the 4th quarter valued at $45,000. Virtus ETF Advisers LLC acquired a new position in shares of Altimmune in the 4th quarter valued at $60,000. Cullen Frost Bankers Inc. acquired a new position in shares of Altimmune in the 4th quarter valued at $72,000. Finally, 180 Wealth Advisors LLC acquired a new position in shares of Altimmune in the 4th quarter valued at $78,000. Institutional investors and hedge funds own 78.05% of the company's stock.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.